Expanding Phase III Study of Tyroserleutide for Injection

Summary

This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment groups：6mg/d Tyroserleutide (injection), or placebo

Timeline

Start

2016-03-24

Primary completion

2016-06-13

Completion

2019-06

Drugs

Indications